RET Fusion
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC (NCT07418879) | Fudan University | 2026-02-05 |
Track RET Fusion automatically
Every clearance here is in the API, with alerts when new ones post.